TRUGLIF 10 MG TABLET

TRUGLIF 10 MG TABLET contains Empagliflozin as its active ingredient. Empagliflozin is classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, a type of medication used in the treatment of type 2 diabetes mellitus. It works by blocking the reabsorption of glucose in the kidneys, thereby increasing urinary glucose excretion and lowering blood sugar levels.

Uses:

TRUGLIF 10 MG TABLET is prescribed for the management of type 2 diabetes mellitus in adults. It is typically used in conjunction with diet and exercise to help improve glycemic control. By increasing urinary glucose excretion, Empagliflozin helps lower blood sugar levels, reducing the risk of complications associated with diabetes.

Administration:

TRUGLIF 10 MG TABLET is taken orally with water, usually once daily. It can be taken with or without food. The dosage may vary depending on individual factors such as the severity of diabetes and the patient’s response to treatment. It’s essential to follow the dosage instructions provided by the healthcare provider for optimal effectiveness.

Side Effects:

Common side effects of TRUGLIF 10 MG TABLET may include urinary tract infections, genital yeast infections, increased urination, thirst, nausea, vomiting, diarrhea, dizziness, and fatigue. These side effects are generally mild and temporary. However, if they persist or become bothersome, individuals should consult their healthcare provider. Serious side effects such as ketoacidosis, kidney problems, and hypoglycemia may occur rarely and require immediate medical attention.

Precautions:

Before taking TRUGLIF 10 MG TABLET, individuals should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. This medication should be used with caution in individuals with kidney impairment or a history of ketoacidosis. Regular monitoring of kidney function and blood sugar levels is recommended during treatment with Empagliflozin.

Contraindications:

TRUGLIF 10 MG TABLET is contraindicated in individuals with a known hypersensitivity or allergy to Empagliflozin or any of the tablet’s components. It should also be avoided in patients with severe kidney impairment or end-stage renal disease. This medication is not suitable for individuals with type 1 diabetes mellitus or diabetic ketoacidosis.

Conclusion:

TRUGLIF 10 MG TABLET, containing Empagliflozin, is used for the management of type 2 diabetes mellitus in adults. By increasing urinary glucose excretion, it helps lower blood sugar levels and improve glycemic control. Patients with type 2 diabetes should consult their healthcare provider to determine if TRUGLIF is an appropriate treatment option for them.